As a wave of up-and-coming cell and gene therapies eye the path to approval in the near future, a combination of uncertainties threaten the waters ahead. A lack of talent, shortage of manufacturing, standardization and shifting infrastructure are just the beginning of a range of potential issues.
Join Precision ADVANCE and Endpoints News as we kick off Cell & Gene Day, where we'll convene three expert panels to find out where the field stands today and explore funding, development and launch strategies to smooth out the ride to commercialization.
Future technologies for cell & gene therapy
Pricing & reimbursement: Unlocking the potential for ATMPs
Funding CGTx: 2022 and beyond
Advanced therapies have been a significant disruptor in healthcare, fundamentally transforming the way diseases are treated. How are advances specific to technology continuing to drive this innovation forward? Join our panel on cutting-edge technologies, their effectiveness, and what we as a sector must still overcome to bring these treatments to the patient.
In this panel you will learn about:
Pressure is being applied to the ‘traditional’ healthcare reimbursement model. As novel therapies continue to propel towards commercialization, healthcare systems and manufacturers are being asked to embrace evidence-based pricing strategies to lessen the burden of upfront costs. Our panelists will discuss how stakeholders across the drug development continuum can work together to manage availability and affordability, while reducing patient-adverse outcomes for these life-saving treatments.
In this panel you will learn about:
The money dump into late-stage drug development came to a screeching halt in 2022. How do investors view the cell & gene landscape and where exactly is it headed? John Carroll and a team of experts will examine this recent downturn and find out what it’ll take to get funding back on track.